Nov 11, 2026 from The Cancer News “Life... All of it:” Sex After Cancer Cancer can change sexual health, but help exists. Oncology experts explain common changes, safe treatments like vaginal estrogen, and how to talk with your doctor.
Nov 11, 2026 from The Cancer News Kidney Cancer in 2026: Real Benefit, Real Trade-offs in Adjuvant Therapy and First-Line Sequencing Explore the evidence behind adjuvant therapy, first-line selection, and treatment sequencing for kidney cancer, including the latest trial data.
Nov 10, 2026 from Your Local Epidemiologist Measles elimination decision brewing, where is the fall vaccination data, and good news you might have missed The Dose (November 10)
Nov 06, 2026 from Your Local Epidemiologist What many get wrong about Amish or Plain Anabaptist communities, measles, and health The U.S.
Nov 05, 2026 from The Cancer News CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026 Relapsed DLBCL treatment now centers on CAR-T eligibility, with bispecific antibodies like mosunetuzumab-polatuzumab filling gaps when CAR-T isn’t accessible.
Nov 05, 2026 from The Cancer News Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations Compare CAR-T and bispecific antibody combinations for primary refractory DLBCL, including ZUMA-7, TRANSFORM, STARGLO and SUNMO trial data and key factors.
Nov 04, 2026 from The Cancer News Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived Review SCLC in 2026: ADRIATIC consolidation durvalumab, tarlatamab full approval, IMforte lurbinectedin maintenance, plus new B7-H3, DLL3, and TROP2 ADC data.
Nov 03, 2026 from The Cancer News Upper GI Cancer Updates: Perioperative Immunotherapy and New HER2-Directed Options MATTERHORN and NeoSUMMIT-01 make perioperative immunotherapy standard in gastric/GEJ cancer, while zanidatamab advances HER2-positive metastatic disease care.
Nov 03, 2026 from The Cancer News When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer A case of severe niraparib-induced thrombocytopenia in BRCA1-mutated ovarian cancer shows how to weigh PARP inhibitor benefit against intolerable toxicity.
Nov 03, 2026 from Your Local Epidemiologist Election stress and your heart, early flu, another CDC leader leaves, and a mom’s hard question about vaccine injury The Dose (November 3)
Nov 02, 2026 from The Cancer News Milk Thistle and Cancer: Why the Warning Label Exists Why does milk thistle carry a cancer warning? Learn what the Prop 65 label means, plus estrogen concerns for hormone-sensitive cancers and chemo interactions.
Nov 02, 2026 from International Journal of Cancer Care and Delivery Advancing Equity in Cancer Clinical Trials: Barriers, Evidence-Based Solutions, and an Integrated Multilevel Model for Underrepresented Populations Diversity among clinical trial participants is essential to assessing the efficacy and toxicity of targeted cancer therapies, yet racial and ethnic minorities remain persistently underrepresented, ...
Oct 30, 2026 from The Cancer News Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It Learn how centers manage cytokine release syndrome after CAR-T and bispecific therapy, from outpatient monitoring to escalation and caregiver support.
Oct 29, 2026 from The Cancer News Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy Learn how prior authorization and specialty pharmacy steering delay oral chemotherapy, add financial toxicity, and how advocacy can help patients.
Oct 28, 2026 from The Cancer News The Post–CAR-T Playbook: What Comes Next? Learn how timing of relapse shapes post-CAR-T treatment in large B-cell lymphoma, from CD20 bispecific combinations to MRD and clinical trials.
Oct 28, 2026 from Your Local Epidemiologist Politics is medicine on a large scale Vote like your health depends on it
Oct 27, 2026 from Your Local Epidemiologist Bird flu in mink, measles double last year, SNAP at an all time low. The Dose (October 27)
Oct 23, 2026 from Your Local Epidemiologist Our story, told in 20 minutes Imagine a room full of biotech heavyweights, all there for panels hosted by STAT News. That’s where I was last week, and I’ll admit I braced myself. Private-sector innovation and creative thinking ...
Oct 22, 2026 from The Cancer News The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond See how CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates are reshaping treatment sequencing for relapsed large B-cell lymphoma.
